Extendicare Inc.

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, SIA.TO has a market cap of 2.2B. Regarding current trading prices, EXE.TO is priced at CA$27.76, while SIA.TO trades at CA$22.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas SIA.TO's P/E ratio is 45.73. In terms of profitability, EXE.TO's ROE is +0.48%, compared to SIA.TO's ROE of +0.07%. Regarding short-term risk, EXE.TO is more volatile compared to SIA.TO. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check SIA.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, DNTL.TO has a market cap of 2.1B. Regarding current trading prices, EXE.TO is priced at CA$27.76, while DNTL.TO trades at CA$11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas DNTL.TO's P/E ratio is -78.57. In terms of profitability, EXE.TO's ROE is +0.48%, compared to DNTL.TO's ROE of -0.02%. Regarding short-term risk, EXE.TO is more volatile compared to DNTL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check DNTL.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, WELL.TO has a market cap of 996.3M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while WELL.TO trades at CA$3.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas WELL.TO's P/E ratio is -130.00. In terms of profitability, EXE.TO's ROE is +0.48%, compared to WELL.TO's ROE of -0.01%. Regarding short-term risk, EXE.TO is less volatile compared to WELL.TO. This indicates potentially lower risk in terms of short-term price fluctuations for EXE.TO.Check WELL.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, DR.TO has a market cap of 298.2M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while DR.TO trades at CA$16.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas DR.TO's P/E ratio is 15.02. In terms of profitability, EXE.TO's ROE is +0.48%, compared to DR.TO's ROE of +0.28%. Regarding short-term risk, EXE.TO is more volatile compared to DR.TO. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check DR.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, AIDX.TO has a market cap of 237.6M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while AIDX.TO trades at CA$0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas AIDX.TO's P/E ratio is -5.40. In terms of profitability, EXE.TO's ROE is +0.48%, compared to AIDX.TO's ROE of -0.39%. Regarding short-term risk, EXE.TO is less volatile compared to AIDX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for EXE.TO.Check AIDX.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, CRRX.TO has a market cap of 221.4M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while CRRX.TO trades at CA$3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas CRRX.TO's P/E ratio is 8.61. In terms of profitability, EXE.TO's ROE is +0.48%, compared to CRRX.TO's ROE of +0.28%. Regarding short-term risk, EXE.TO is more volatile compared to CRRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check CRRX.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, DRDR.TO has a market cap of 49.4M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while DRDR.TO trades at CA$0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas DRDR.TO's P/E ratio is -0.83. In terms of profitability, EXE.TO's ROE is +0.48%, compared to DRDR.TO's ROE of -1.02%. Regarding short-term risk, EXE.TO is less volatile compared to DRDR.TO. This indicates potentially lower risk in terms of short-term price fluctuations for EXE.TO.Check DRDR.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, GTMS.TO has a market cap of 28.6M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while GTMS.TO trades at CA$0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas GTMS.TO's P/E ratio is -0.45. In terms of profitability, EXE.TO's ROE is +0.48%, compared to GTMS.TO's ROE of +15.74%. Regarding short-term risk, EXE.TO is less volatile compared to GTMS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for EXE.TO.Check GTMS.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, NUMI.TO has a market cap of 16M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while NUMI.TO trades at CA$0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas NUMI.TO's P/E ratio is -0.63. In terms of profitability, EXE.TO's ROE is +0.48%, compared to NUMI.TO's ROE of +11.51%. Regarding short-term risk, EXE.TO is more volatile compared to NUMI.TO. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check NUMI.TO's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, EPW.CN has a market cap of 4.1M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while EPW.CN trades at CA$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas EPW.CN's P/E ratio is -0.27. In terms of profitability, EXE.TO's ROE is +0.48%, compared to EPW.CN's ROE of +0.47%. Regarding short-term risk, EXE.TO is more volatile compared to EPW.CN. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check EPW.CN's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, CALM.CN has a market cap of 2.8M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while CALM.CN trades at CA$0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas CALM.CN's P/E ratio is -0.11. In terms of profitability, EXE.TO's ROE is +0.48%, compared to CALM.CN's ROE of +3.14%. Regarding short-term risk, EXE.TO is more volatile compared to CALM.CN. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check CALM.CN's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, OMIC.CN has a market cap of 2.3M. Regarding current trading prices, EXE.TO is priced at CA$27.76, while OMIC.CN trades at CA$0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas OMIC.CN's P/E ratio is -4.50. In terms of profitability, EXE.TO's ROE is +0.48%, compared to OMIC.CN's ROE of -0.83%. Regarding short-term risk, EXE.TO is more volatile compared to OMIC.CN. This indicates potentially higher risk in terms of short-term price fluctuations for EXE.TO.Check OMIC.CN's competition here

EXE.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXE.TO stands at 2.6B. In comparison, MEDI.NE has a market cap of 17.8K. Regarding current trading prices, EXE.TO is priced at CA$27.76, while MEDI.NE trades at CA$0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXE.TO currently has a P/E ratio of 25.01, whereas MEDI.NE's P/E ratio is -0.02. In terms of profitability, EXE.TO's ROE is +0.48%, compared to MEDI.NE's ROE of N/A. Regarding short-term risk, EXE.TO is less volatile compared to MEDI.NE. This indicates potentially lower risk in terms of short-term price fluctuations for EXE.TO.Check MEDI.NE's competition here